Downloads
Thank you for visiting our web site. Please click on the links below to download more information about our company, services and research.
Canadian Drug Claims Database
PMPRB Reference Guide
RTI Health Solutions Overview Brochure
Health Economics
Database Analysis
Patient-Reported Outcomes
Psychometrics
Survey Research and Data Collection
Outcomes Research and Regulatory Strategy
Product Value Dossiers
Pricing and Reimbursement
Specialty Canadian Pricing and Reimbursement Strategies
Health Preference Assessment
Epidemiology
Therapeutic Risk Management
Prospective Observational Studies
Epidemiology Literature Reviews
Pharmacovigilance
Medical Monitoring
Medical Consulting and Writing
Biostatistics
Johnson, F.R., and A.B. Hauber. June 2008. Quantifying Patient Benefit-Risk Tradeoff Preferences: A Brief Introduction.
Goldberg, J.F., L.D. Mcleod, S.E. Fehnel, L.R. Hamm, and K. Gilchrist. Development and Evaluation of a New Patient-Reported Instrument: the Bipolar Functional Status Questionnaire.
Sherrill, B., M.M. Amonkar, Y. Wu, C. Hirst, S.H. Stein, M.D. Walker, and J. Cuzick. Disease Progression as a Predictor of Overall Survival in Metastatic Breast Cancer: A Meta-analysis.
Wu, Y., A. Segreti, D. Cella, A. DiLeo, M.M. Amonkar, M. Koehler, M. Arbushites, and M.D. Walker. Lapatinib Plus Paclitaxel Versus Paclitaxel Alone for First-Line Metastatic Breast Cancer in ErbB2-Positive Patients: Quality-of-Life Results.
Zhou, X., A. Segreti, D. Cella, D. Cameron, C. Geyer, M.M. Amonkar, S.H. Stein, and M.D. Walker. Lapatinib + Capecitabine vs. Capecitabine alone for ErbB2+ Metastatic Breast Cancer: Quality-of-Life Assessment.
Zhou, X., A. Segreti, D. Cella, D. Cameron, C. Geyer, M.M. Amonkar, S.H. Stein, and M.D. Walker. Lapatinib Plus Capecitabine Versus Capecitabine Alone for ErbB2-Positive Metastatic Breast Cancer: Quality-of-Life Assessment.
Perez-Gutthann, S.. Lessons Learned from Epidemiologic Studies and Clinical Trials.
DeStefano, F., C.D. Heath, D.B. Currivan, and S.F. Wetterhall. Influenza Vaccination Among Adults in Four North Carolina Counties, 2007–2008.
Gilsenan, A.W., A. Ladner, C. Varas-Lorenzo, T. Kold Olesen, C. Karup, and E.B. Andrews. Incidence of Cardiovascular and Cerebrovascular Events Among Men With Prostate Cancer.
Midkiff, K., C.B. Johannes, and A.K. Mohan. Utility of Multiple Databases in a Surveillance Program for Prescription Narcotic Analgesics.
Barrett, A.M., A.D. Colosia, K.S. Boye, and O. Oyelowo. Burden of Obesity: 10-Year Review of the Literature on Costs in Nine Countries.
Barrett, A.M., K.S. Boye, and O. Oyelowo. Burden of Obesity: 10-Year Review of the Literature on Obesity Prevalence in Nine Countries.
Brennan, V.K., and S.E. Wolowacz. A Systematic Review of Breast Cancer Utility Weights.
Candrilli, S., R. Balkrishnan, and S.H. O'Brien. The Effect of Injury Severity on the Incidence and Resource Utilization-Related Outcomes of Deep Vein Thrombosis Among Pediatric Trauma Admissions in the United States.
Copley-Merriman, C., S.E. Fehnel, J. Chandler, and D. Wild. Obtaining a Patient-Reported Outcomes Label Claim: What Evidence Do You Need?.
Davis, K.L., D. Mitra, J. Medjedovic, C. Beam, and V.K. Rustgi. Direct Economic Burden of Chronic Hepatitis C Virus in a Large Managed Care Population.
Davis, K.L., D. Mitra, and S. Kotapati. Direct Economic Burden of High-Risk and Metastatic Melanoma: Evidence From the SEER-Medicare Linked Database.
Hauber, A.B., A.F. Mohamed, F.R. Johnson, H. Falvey, and E. Snyder. Preferences for Oral Antidiabetic Agents Among People With Type 2 Diabetes.
Kotapati, S., D. Mitra, K.L. Davis, and U. Iloeje. Predictors of Treatment Choice in High-Risk and Metastatic Melanoma: Evidence From Linked Electronic Medical Records and Administrative Claims Data.
Mitra, D., K.L. Davis, J. Medjedovic, C. Beam, and V.K. Rustgi. Health Care Utilization and Costs Associated with Chronic Hepatitis C in a Managed Care Population.
Mitra, D., S. Candrilli, K.L. Davis, and B. Bapat. Inpatient Costs and Outcomes Associated With Chronic Hepatitis C-Related Complications in the United States.
Mitra, D., K.L. Davis, S. Kotapati, and U. Iloeje. Real-World Treatment Patterns in High-Risk and Metastatic Melanoma: Evidence From the SEER-Medicare Linked Database.
Mohamed, A.F., F.R. Johnson, A.B. Hauber, D. Meddis, and S. Wagner. Preferences for Onset of Effect of Combination Maintenance Medication Among Asthma Patients.
DiBenedetti, D., and C.D. Hill. Adherence Among Patients with Parkinson’s Disease Taking Ropinirole Immediate Release At Least Three Times Daily.
DiBenedetti, D., J.A. Sollano, and R.L. Kolotkin. The Impact of Being Overweight on Health-Related Quality of Life in Type 2 Diabetic Patients: Patient Interviews.
Sherrill, B., C. Hirst, Y. Wu, M.M. Amonkar, and S.H. Stein. Retrospective Pooled Analysis to Assess Correlation Between Time to Progression and Overall Survival in Patients With Breast Cancer.
Mauskopf, J., A.J. Brogan, C. Malmberg, and P. Hwang. Cost-Effectiveness of Darunavir for the Management of HIV-Infected, Treatment-Experienced Adults in Canada.
Sherrill, B.H., A.A. Allshouse, M.M. Amonkar, and S.H. Stein. Lapatinib plus capecitabine versus capecitabine alone for metastatic breast cancer: Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST).
Sherrill, B., A.A. Allshouse, and S.H. Stein. Lapatinib Plus Capecitabine Versus Capecitabine Alone for Metastatic Breast Cancer: Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST).
Davis, K.L., S.D. Candrilli, and H.M. Edin. Prevalence and Cost Impact of Nonadherence with Antiepilepsy Drugs Among Adults in a Managed Care Population.
Earnshaw, S.R., V. Sikirica, N.S. Roskell, P.R. Shannon, S. Beard, J. Schein, D. Doshi, and C. Janagap. Economic Analysis of Short-Course Levofloxacin Versus Amoxicillin/Clavulanate in Treating Acute Bacterial Exacerbations of Chronic Bronchitis.
Graham, C.N., S.R. Earnshaw, and M. Saunders. Assessing the Impact of Smoking Cessation Therapies on a Managed Care Organization's Budget Using Census Region and State-Specific Smoking Estimates.
Candrilli, S.D., E. Lee, S.S.K. Tang, S. Bassin, H.J. Laird, S.S. Levy, and N.D. Wong. Cardiovascular Risk in US Urban Hispanic Populations: Regional Data From Community Outreach Programs.
Lee, E., S.S.K. Tang, S.D. Candrilli, S. Bassin, H.J. Laird, S.S. Levy, and N.D. Wong. Regional Differences in the Prevalence of Hypertension and Dyslipidemia in US Urban Hispanic Populations.
Tang, S.S.K., E. Lee, S.D. Candrilli, H.J. Laird, S.S. Levy, S. Bassin, and N.D. Wong. Prevalence, Treatment, and Control of Hypertension and/or Dyslipidemia Among Hispanic Adults in US Communities.
Hirst, C., and E. Andrews. International Therapeutic Risk Management.
Sherrill, B., A.A. Allshouse, M.M. Amonkar, M.D. Walker, and S.H. Stein. A Comparison of Lapatinib Plus Capecitabine Versus Capecitabine Alone for Quality-Adjusted Survival in Metastatic Breast Cancer: a Q-TWiST Analysis.
Beard, S.. Developing Health Economic Models for Submission to Health Authorities as Evidence of Product Value.
Devine, S.T., S. West, E. Andrews, P. Tennis, S. Eaton, J. Thorp, and A. Olshan. The Identification of Pregnancies Within The Full Feature-General Practice Research Database.
Devine, S.T., S. West, E. Andrews, P. Tennis, S. Eaton, J. Thorp, and A. Olshan. The Validation of Neural Tube Defects in the General Practice Research Database.
Gilsenan, A.W., K. Midkiff, Y. Wu, R. Martin, D.N. Masica, and E. Andrews. Factors Associated With Interview Completion Rates in a Surveillance Study of Osteosarcoma and Antecedent Exposures.
Midkiff, K., A. Gilsenan, R. Martin, D.N. Masica, and E. Andrews. Characteristics of Patients in a Postmarketing Osteosarcoma Surveillance Study.
Midkiff, K., C.B. Johannes, and A.K. Mohan. Strengths and Limitations of Drug Abuse Warning Network Data Used in a Surveillance Study.
Perez-Gutthann, S.. Risk Management Planning: An industry viewpoint – Achievement and Problems.
Wang, J., B. Sherrill, and W. Irish. Determining Sample Size For Postmarketing Surveillance of Rare Adverse Events.
Davis, K.L., S.D. Candrilli, D. Mitra, B.J. Tortella, and A.V. Joshi. The Effect of Injury Severity and Trauma Center Designation on Inpatient Costs and Outcomes in Hospital Admissions for Traumatic Injury in the United States.
Graham, J.B., S.R. Earnshaw, J. Castelli-Haley, M. Oleen-Burkey, and K.P. Johnson. Cost-effectiveness of Glatiramer Acetate and Natalizumab in Relapsing-Remitting Multiple Sclerosis in the Presence of Long-Term Clinical Evidence.
Johnson, F.R., A.B. Hauber, A.F. Mohamed, C. Leibman, H.M. Arrighi, A.S. Zbrozek, and P. Coplan. Alzheimer’s Disease Progression Healthy-Year Equivalents: Stated Risk-benefit Trade-off Preferences.
Leeuwenkamp, O., R. Morlock, C. Bell, A.J. Brogan, and J. Mauskopf. Costs and Outcomes of Atypical Antipsychotics for the Treatment of Acute Schizophrenia.
Mitra, D., K.L. Davis, S.D. Candrilli, B.J. Tortella, and A.V. Joshi. Inpatient Costs and Outcomes Associated With Pediatric Traumatic Injury in the United States by Injury Severity and Trauma Center Designation.
Mohamed, A.F., A.B. Hauber, F.R. Johnson, M.E. Watson, and J.E. Hernandez. Incorporating Probabilistic Attributes in a Stated-Choice Risk-Benefit Survey.
Zyczynski, T.M., S.M. Beard, S.R. Earnshaw, and C.L. McDade. Cost-effectiveness Analysis of the Use of Iodixanol Compared to Iohexol in the United Kingdom.
Candrilli, S., K.L. Davis, D. Mitra, B.J. Tortella, and A.V. Joshi. Inpatient Costs and Outcomes Associated With Traumatic Injury in the United States by Injury Severity and Trauma Center Designation.
Earnshaw, S.R., M.R. Wilson, and A.V. Joshi. Cost-Effectiveness of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage over a Two-Year Managed Care Enrollment Period.
Mcleod, L.D., S.E. Fehnel, L.J. Zografos, S.D. Sander, T.G. Curtis, and H. Shah. The Impact of Restless Legs Syndrome on Various Dimensions of Life: Results of a Web-Based Patient Survey.
Mitra, D., K.L. Davis, and R. Baran. Health Care Utilization and Costs Associated With Constipation (C-ONLY) and Co-Occurring Irritable Bowel Syndrome and Constipation (IBS+C) Compared to Migraine in a Large Managed Care Population.
Ozdemir, S., A.F. Mohamed, G. Huiber, and F.R. Johnson. How Good Is Good Enough? Internal Validity of Stated Preferences for Drug Therapies.
Sherrill, B.H., C. Hirst, M.M. Amonkar, and S.H. Stein. Correlation Between Time to Progression and Overall Survival in Patients With Metastatic Breast Cancer.
Perez-Gutthann, S.. Evaluación de Señales de Alerta en el contexto global de la Gestión de Riesgos.
Davis, K.L., S.D. Candrilli, A.V. Joshi, and B.J. Tortella. The Direct Economic Burden of Blunt and Penetrating Trauma Among the Elderly Population.
Perez-Gutthann, S.. What Have We Learned from Safety Cases for New Drug Development? Industry Responding to Learning from Safety Cases.
Davis, K.L., J.K. Allen, J. Kirsch, K.H. Davis, and H.M. Edin. The Prevalence of Treatment Non-Adherence Among Patients with Parkinson's Disease in a United States Managed Care Population.
Williams, R.E., D. DiBenedetti, X. Zhou, S.E. Fehnel, and R.V. Clark. Healthcare Seeking Behavior Among Peri- and Post-Menopausal Women: Results from the US Population-Based MEPI Study.
Williams, R.E., D. DiBenedetti, X. Zhou, S.E. Fehnel, and R.V. Clark. The Menopause Epidemiology (MEPI) Study: Vasomotor Symptom Results from a Large Population-Based Study.
Earnshaw, S.R., A.V. Joshi, M.R. Wilson, and J. Rosand. Cost-effectiveness of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage.
Earnshaw, S.R., S.M. Beard, N.O. Lynch, A. Cooper, W. Cowell, and H. Middelhoven. A Comparison of the Cost-Effectiveness of Bisphosphonates Using Persistence Data from a UK Propsective RCT.
Candrilli, S., and J. Mackell. Effect of NCEP ATP III Guideline Revisions on the Prevalence of Dyslipidemia Among the Elderly: Evidence from NHANES.
Davis, K.L., J. Mauskopf, W. Chow, J. Chao, and B. Seal. Titration and persistence with tamsulosin among men with benign prostatic hyperplasia in a large managed care population.
Earnshaw, S.R., A.V. Joshi, and M.R. Wilson. Cost-effectiveness of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage: A US Managed Care Perspective.
Earnshaw, S.R., and J. Gricar. Good Practices for High Quality Decision Analytic Models.
Graham, C.N., S.R. Earnshaw, D.G. Smith, S. Hogue, J. Gitchell, H. Marsh, W. Becker, and M. Saunders. Assessing the Impact of Smoking Cessation Therapies on a Managed Care Organization's Budget.
Davis, K.L., A.V. Joshi, B.J. Tortella, and S.D. Candrilli. The Direct Economic Burden of Blunt and Penetrating Trauma in a Managed Care Population.
Rubino, A., D. Mines, N.S. Roskell, P. Tennis, E. Andrews, and S. Welch. Risk of Suicide During Venlafaxine Treatment Compared with Citalopram, Fluoxetine, and Dothiepin Treatment: A Population-based Analysis in the United Kingdom.
Johnson, F.R., and G.L. Van Houtven. Evaluating Risk-Benefit Tradeoffs and Health-Related Utility: A Comparison of Standard Gamble and Conjoint Methods.
Johnson, F.R., S. Ozdemir, A.F. Mohamed, D. Marshall, and K. Philips. How Does price Matter in Healthcare Stated-Choice Surveys?.
Ozdemir, S., F.R. Johnson, C. Mansfield, S. Hass, and J. White. Are Crohn’s Parents More Risk Averse Than Adult Patients? Acceptable Tradeoffs between Efficacy and Adverse-Event Risks.
Zlateva, G.P., J.C. Javitt, S.R. Earnshaw, A.M. Pliel, C.N. Graham, A.J. Brogan, S. Shah, and A.P. Adamis. Cost-effectiveness Model for Age-related macular Degeneration: Comparing Early and Late Macugen Treatment.
Earnshaw, S.R., S.M. Beard, N.O. Lynch, and W. Cowell. Ibandronate in the treatment of postmenopausal osteoporosis: a cost-effectiveness analysis in the UK.
Mladsi, D.M.. Developing Health Economic Models for Assessing Cost-Effectiveness and Product Value.
Kauf, T.L., M.S. Saag, M. Kitahata, B. Gazzard, S.R. Earnshaw, C.N. Graham, E.A. Davis, A. Shearer, and J. Mauskopf. Simulation Modeling of Adherence and Resistance on Long-Term Outcomes in HIV.
Gilsenan, A., X. Zhou, F. Coste, and A.A. Allshouse. Comparison of Data from a US National Survey (NHANES) with Data from a Cohort Recruited from the Internet.
Johnson, F.R., S. Ozdemir, E. Andrews, S. Hass, D.P. Miller, J. White, C. Siegel, and B. Sands. Patients' Willingness to Accept Risk-Benefit Tradeoffs in Treating Crohn's Disease.
Lanza, L.L., L. Wang, T. Simon, and W. Irish. Risk of Selected Outcomes After Solid Organ Transplantation: A Literature Review.
Nyberg, F., S. Hada, and K.J. Rothman. Iressa and Interstitial Lung Disease (ILD) in Japan - Lessons from a Large Nested Case-Control Study to Evaluate a Safety Issue.
Rubino, A., L. McQuay, M. Kvasz, and P. Tennis. Population-Based Study of Time to Insulin After Failure of Oral Antidiabetic Therapy in Type 2 Diabetes in the UK.
Rubino, A., S.J. Evans, and L. Smeeth. Risk of Stroke During Treatment with Atypical and Conventional Antipsychotics: A Population-Based Study in the United Kingdom.
Rubino, A., N.S. Roskell, P. Tennis, D. Mines, S. Weich, and E. Andrews. Risk of Suicide During Venlafaxine and Comparator Antidepressants Treatment.
Sanchez Matienzo, D., L.L. Lanza, L.J. Mcquay, L. Gutierrez, and S. Perez-Gutthann. Descriptive Study of Users of Depo-Medroxyprogesterone Acetate (DMPA) in the MHRA GPRD.
Varas-Lorenzo, C., L. McQuay, S. Eaton, I. Saez-Lloret, M. Melero-Montes, D. Miller, and S. Perez-Gutthann. Characterization of US Adult Users of Antihypertensive Medications.
Wang, J., A.A. Allshouse, and W. Irish. Underestimation of Variance Due to Using Simple Random Sampling Statistical Methods Applied to Data Obtained from a Cluster Sampling Design.
Bala, M.V., J.A. Mauskopf, and G.A. Zarkin. Presenting Uncertainty Around Cost-Effectiveness Estimates to Decision Makers: How Sure Are We?.
Bell, C.F., J.B. Graham, S.R. Earnshaw, M. Oleen-Burkey, J. Castelli-Haley, and K. Johnson. Assessing the Cost-Effectiveness of Immunomodulatory Therapies for Relapsing-Remitting Multiple Sclerosis Based on Long-Term Data.
Candrilli, S.D., and J.A. Mauskopf. How Much Does a Day in the Hospital Cost?.
Earnshaw, S.R., C.N. Graham, M.M. Amonkar, and C. Barr. The Cost-Effectiveness of Ibandronate in the Treatment of Postmenopausal Osteoporosis in the US.
Johnson, F.R., and G.L. Van Houtven. Quantifying Patients' Risk-Benefit Tradeoff Preferences: A Conceptual and Empirical Comparison of Methods.
Johnson, F.R., S. Ozdemir, C.A. Mansfield, B. Sands, C. Siegel, S. Hass, D. Miller, and J. White. Weighing Treatment Benefits Against Treatment Risks: Crohn’s Disease Patients’ Willingness to Accept Risk-Benefit Tradeoffs.
Kolotikin, R.L., R. Crosby, C. Radigue, and A.A. Allshouse. Impact of Abdominal Obesity on Health-Related Quality of Life.
Mauskopf, J.A., G.S. Simon, C. Nimsch, and A.A. Krishnan. Measurement of Utility Losses in Depression.
McCrink, L., S.M. Beard, and T. Le. The Relationship Between Health-Related Quality of Life (HRQOL) and Pain Response in Patients with Diabetic Peripheral Neuropathic Pain.
Mladsi, D.M., and A.M. Barrett. Winners and Losers: Patterns in Economic Evaluations of Anti-Epileptic Drugs.
Candrilli, S.D., K.L. Davis, A.V. Joshi, and B.J. Tortella. Healthcare Utilization and Costs Associated with Blunt and Penetrating Trauma in a United States Managed Care Population.
Earnshaw, S.R., M.R. Wilson, and A.V. Joshi. Budgetary Impact Analysis of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage: A US Health Plan Perspective.
Hauber, B., F.R. Johnson, and S. Ozdemir. Conjoint Analysis QALYs for Acute Conditions: An Application to Vasomotor Symptoms.
Javitt, J.C., S.E. Wolowacz, N.S. Roskell, F. Maciver, S. Kelly, A.M. Pleil, and G.P. Zlateva. Cost-Effectiveness of Pegaptanib in Age-Related Macular Degeneration: The Impact of Differences Between USA and UK Health Care Systems.
Johnson, F.R., S. Ozdemir, C.A. Mansfield, S. Hass, and J. White. Are Adults More Averse to Treatment Risks for Their Children Than They Are for Themselves?.
Wolowacz, S.E., N.S. Roskell, F. Maciver, and S. Kelly. Cost-Utility Analysis for Pegaptanib in Age-Related Macular Degeneration in the UK: The Impact of Demographic and Disease Characteristics.
Wolowacz, S.E.. The National Institute for Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) Process: An Update on the First Round of Submissions.
Zhou, X., C. Radigue, A.A. Allshouse, and A. Gilsenan. In Europe, How Representative are Overweight/Obese Subjects Recruited Via the Internet?.
Earnshaw, S.R., Y. Moride, A. Moshyk, and S. Rochon. Cost-effectiveness of Macugen Compared to Photodynamic Therapy (PDT) with Verteporfin and Standard Care in the Treatment of Subfoveal Wet Age-Related Macular Degeneration (AMD) in the Elderly in Canada.
Schnitzler, M.A., S.R. Earnshaw, C.N. Graham, W.D. Irish, and R. Sato. Lifetime Cost-Effectiveness of Calcineruin Inhibitor-Free Immunosuppressive Treatment After De Novo Renal Transplantation.
Britt, D.M., S.E. Fehnel, A.L. Granger, X. Zhou, and R. Williams. Quality of Life and the Prevalence of Vasomotor Symptoms in a Population-Based Sample of Peri- and Post-Menopausal Women.
Fehnel, S., L.D. Mcleod, H.M. Edin, and S.L. Hogue. Psychometric Evaluation of the Motivation and Energy Inventory –Short Form (MEI-SF).
Mcleod, L.D., S.E. Fehnel, M.M. Wills, L.R. Hamm, and K. Gilchrist. Psychometric Validation of a Patient-Reported Instrument Assessing Functional Status in Bipolar Disorder.
